What is Optellum?
Optellum operates at the intersection of healthcare and artificial intelligence, providing sophisticated decision-support software designed to aid physicians in the early detection and optimal management of lung diseases. Founded with the mission to ensure every patient with lung disease receives timely diagnosis and treatment at the earliest, most curable stages, Optellum's technology extends beyond lung cancer to encompass other critical conditions such as interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD). The company maintains a dual presence with headquarters in Oxford, UK, and a U.S. office at the Texas Medical Center in Houston, TX. Its development has been supported by grants from prominent organizations including InnovateUK, the National Institute for Health Research (NIHR), and the NHS AI Lab.
How much funding has Optellum raised?
Optellum has raised a total of $14M across 1 funding round:
Series A
$14M
Series A (2022): $14M with participation from IQ Capital, Mercia Technologies, Intuitive Venture Partners, and Black Opal Ventures
Key Investors in Optellum
IQ Capital
IQ Capital is a venture capital firm specializing in deep-tech investments, including AI and machine learning. They focus on companies with the potential for global market dominance and invest from seed to Series A stages.
Mercia Technologies
Mercia Asset Management provides equity and debt financing to UK businesses, offering venture capital and private equity to support growth and scale-up initiatives.
Intuitive Venture Partners
Intuitive Venture Partners is a venture investment bank that structures and executes private placements for technology and healthcare companies, focusing on financing innovative breakthroughs.
What's next for Optellum?
This latest round of major strategic investment positions Optellum for accelerated growth and expanded market penetration. The substantial capital infusion, part of its $14M in total financing, will likely fuel further development of its AI platform, enhance clinical validation, and support broader adoption across healthcare systems. As a Series A company, Optellum is poised to scale its operations, solidify its position as a leader in AI-driven respiratory care, and potentially extend its diagnostic capabilities to a wider spectrum of pulmonary conditions, reinforcing its commitment to improving patient outcomes globally.
See full Optellum company page
